Ethicon, a subsidiary of Johnson & Johnson, received approval from the United States Food and Drug Administration for its Enseal G2, a new type of tissue sealer.
According to a press release by the company, the Enseal G2 is the first product on the market that gives surgeons the ability to take a perpendicular approach when sealing blood vessels. In particular, a perpendicular approach could be useful in operations involving complex anatomy. This includes gynecological and colorectal surgeries. In these surgeries, it can be very difficult for a physician to close an incision.
According to information from Ethicon, perpendicularly-sealed vessels are stronger than those closed at oblique angles. Stronger seals may reduce the need for repeat surgeries and may reduce the risk of internal bleeding.
The device uses the company’s I-Blade system. The I-Blade system is designed to provide a uniform and consistent seal with minimal thermal spread. Through the use of offset electrode configuration tech, the device can work with minimal errant heat.
Dr. Joe Amaral is the chief scientific officer at Ethicon. In prepared remarks, he said, "ENSEAL® G2 Articulating builds on an existing portfolio of advanced bipolar tissue sealers designed to give surgeons confidence and choice in surgery." He continued, "Ethicon continues to work with surgeons around the world and across specialties to design innovations to help surgeons deliver the best outcomes based on the unique needs of their patients and procedures."
- Additive Manufacturing 101: How the Future of Product Development and Manufacturing is Changing - Video
- Microfluidics—A Powerful Technology for Diagnostic and Medical Product Development - Video
- Going Beyond Colour Matching . - Video
- Metal Injection Molding(MIM) for Precision metal components manufacturing - Supplier Resource
- Usage Temperatures of Piezoceramic Materials - Supplier Resource
- Breaking the Rules – Design Ideation and Innovation - Supplier Resource